Cargando…
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420789/ https://www.ncbi.nlm.nih.gov/pubmed/28140392 http://dx.doi.org/10.1038/leu.2017.47 |
| _version_ | 1783234466268839936 |
|---|---|
| author | Chanan-Khan, A Egyed, M Robak, T Martinelli de Oliveira, F A Echeveste, M A Dolan, S Desjardins, P Blonski, J Z Mei, J Golany, N Zhang, J Gribben, J G |
| author_facet | Chanan-Khan, A Egyed, M Robak, T Martinelli de Oliveira, F A Echeveste, M A Dolan, S Desjardins, P Blonski, J Z Mei, J Golany, N Zhang, J Gribben, J G |
| author_sort | Chanan-Khan, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5420789 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-54207892017-05-19 Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) Chanan-Khan, A Egyed, M Robak, T Martinelli de Oliveira, F A Echeveste, M A Dolan, S Desjardins, P Blonski, J Z Mei, J Golany, N Zhang, J Gribben, J G Leukemia Letter to the Editor Nature Publishing Group 2017-05 2017-02-17 /pmc/articles/PMC5420789/ /pubmed/28140392 http://dx.doi.org/10.1038/leu.2017.47 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Chanan-Khan, A Egyed, M Robak, T Martinelli de Oliveira, F A Echeveste, M A Dolan, S Desjardins, P Blonski, J Z Mei, J Golany, N Zhang, J Gribben, J G Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title_full | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title_fullStr | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title_full_unstemmed | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title_short | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) |
| title_sort | randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the origin trial) |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420789/ https://www.ncbi.nlm.nih.gov/pubmed/28140392 http://dx.doi.org/10.1038/leu.2017.47 |
| work_keys_str_mv | AT chanankhana randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT egyedm randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT robakt randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT martinellideoliveirafa randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT echevestema randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT dolans randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT desjardinsp randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT blonskijz randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT meij randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT golanyn randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT zhangj randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial AT gribbenjg randomizedphase3studyoflenalidomideversuschlorambucilasfirstlinetherapyforolderpatientswithchroniclymphocyticleukemiatheorigintrial |